<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03659448</url>
  </required_header>
  <id_info>
    <org_study_id>SGM-CLIN03</org_study_id>
    <nct_id>NCT03659448</nct_id>
  </id_info>
  <brief_title>Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer</brief_title>
  <official_title>Multicenter, Open-label, Randomized, Controlled, Parallel Arms Clinical Study on Performance of SGM-101, a Fluorochrome-labeled Anti-CEA Monoclonal Antibody, for Delineation of Primary/Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Surgimab</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Surgimab</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The performance of SGM-101, an intraoperative imaging agent, will be compared to that of
      standard &quot;white light&quot; visualization during surgical resections of colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The performance of SGM-101, a fluorochrome-labeled anti-carcinoembryonic antigen (CEA)
      monoclonal antibody intraoperative imaging agent for the delineation of primary and recurrent
      tumor and metastases in patients undergoing curative surgery for colorectal cancer will be
      compared to that of standard &quot;white light&quot; visualization in a multicenter, open-label,
      randomized, controlled, parallel arms clinical study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two parallel arms consisting of a treatment arm of patients who will receive the study drug and subsequently undergo surgical resections under both &quot;standard &quot;white light&quot; conditions and then NIR, and a no treatment arm to whom the study drug will not be administered and who will undergo surgical resections under standard &quot;white light&quot; conditions only.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical resection histopathology.</measure>
    <time_frame>Through completion of surgery, up to 9 weeks.</time_frame>
    <description>Comparison of surgical resections using histopathology as standard of truth..</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a single dose of the study drug, SGM-101, and subsequently undergo surgical resections under both &quot;standard &quot;white light&quot; conditions and then NIR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will not be administered the study drug, SGM-101, and will undergo surgical resections under standard :white light&quot; conditions only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGM-101</intervention_name>
    <description>A fluorochrome-labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody intraoperative imaging agent.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients should be scheduled for curative colorectal cancer surgery of primary cT4
             colon cancer or primary cT3/4 rectal cancer, recurrent colorectal cancer or peritoneal
             metastasized colorectal cancer.

          -  Female patients must be of non-child-bearing potential (i.e., women with functioning
             ovaries who have a documented tubal ligation or hysterectomy, ovariectomy or women who
             are post-menopausal). Women of child-bearing potential will be included provided that
             they have a negative urine pregnancy test at the day of the injection and agree to
             practice adequate contraception for 30 days prior to administration of investigational
             product, and 30 days after completion of injection.

        Exclusion Criteria:

          1. Other malignancies, either currently active or diagnosed in the last 5 years, except
             for adequately treated in situ carcinoma of the cervix and basal or squamous cell skin
             carcinoma;

          2. Primary appendiceal cancer;

          3. Laboratory abnormalities defined as:

               -  Aspartate AminoTransferase, Alanine AminoTransferase, Gamma Glutamyl Transferase)
                  or Alkaline Phosphatase levels above 5 times the ULN or;

               -  Total bilirubin above 2 times the ULN or;

               -  Serum creatinine above 1.5 times the ULN or;

               -  Absolute neutrophils counts below 1.5 x 109/L or;

               -  Platelet count below 100 x 109/L or;

               -  Hemoglobin below 4 mmol/L (females) or below 5 mmol/l (males);

          4. Known positive test for human immunodeficiency virus (HIV), hepatitis B surface
             antigen (HBsAG) or hepatitis C virus (HCV) antibody or patients with untreated serious
             infections;

          5. Any condition that the investigator considers to be potentially jeopardizing the
             patient's well-being or the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex L. Vahrmeijer,, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center, Leiden, The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Warner, JD, MPA</last_name>
    <phone>8123257657</phone>
    <email>johna.warner@outlook.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Françoise Cailler, PhD</last_name>
    <phone>+33 467 798 381</phone>
    <email>fcailler@surgimab.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moores Cancer Center - UCSD Health</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia L Ramamoorthy, MD</last_name>
      <phone>858-657-6100</phone>
      <email>sramamoorthy@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dad Shakeela, Ph.D.</last_name>
      <phone>(858) 822-5376</phone>
      <email>sdad@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sonia L Ramamoorthy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Lowy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joel Baumgartner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebekah White, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kaitlyn Kelly, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Sicklick, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole Lopez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jula Veerapong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samuel Eisenstein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David J MARON, MD</last_name>
      <phone>954-659-5278</phone>
      <email>MAROND@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Maria MEJIA, BS, CCRP</last_name>
      <phone>(954) 659-5888</phone>
      <email>MEJIAGM@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>David J Maron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Wexner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric Weiss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanna DaSilva, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dana Sands, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Conrad Simpfendorfer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mayank Roy, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rocco Ricciardi, MD</last_name>
      <email>RRICCIARDI1@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Caitlin Stafford</last_name>
      <phone>617-643-7869</phone>
      <email>CSTAFFORD2@partners.org</email>
    </contact_backup>
    <investigator>
      <last_name>Rocco Ricciardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Horoko Kunitake, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Hodin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Liliana Bordeianou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Perelman Center for Advanced Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Singhal, MD</last_name>
      <email>Sunil.Singhal@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Najjia Mahmoud, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sunil Singhal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen, Klinik für Allgemein- Viszeral- und Kinderchirurgie</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Sperling, MD</last_name>
      <phone>+49 551 39 7989</phone>
      <email>Jens.Sperling@med.uni-goettingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Johanna Kreutzer, Ph.D.</last_name>
      <email>johanna.kreutzer@med.uni-goettingen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H J Rutten, MD, PhD</last_name>
      <phone>+31 40 2397150</phone>
      <email>harm.rutten@catharinaziekenhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2333 CL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander L Vahrmeijer, MD, Ph.D.</last_name>
      <phone>+31 71 5262309</phone>
      <email>a.l.vahrmeijer@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Ruben P Meijer, MD</last_name>
      <phone>‭+31 71 7517143</phone>
      <email>R.P.J.Meijer@lumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelis Verhoef, MD</last_name>
      <email>c.verhoef@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Job Kooten, MD</last_name>
      <email>j.kooten@erasmusmc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Cornelis Verhoef, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fluorescence</keyword>
  <keyword>Cancer</keyword>
  <keyword>SGM-101</keyword>
  <keyword>Surgery</keyword>
  <keyword>Colorectal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

